The Ledger

1.5 billion dollars: that is what a Swiss plasma-therapeutics maker just locked in for its first-ever US factory, a deal that nearly died in a weeks-long fight over who pays for it. Octapharma announced July 29, 2026 that it will build its first US manufacturing and production site at Palmetto Research Park in Rock Hill, South Carolina, the former site of a Carolina Panthers headquarters project that never got built; the 1.5 billion dollar investment is expected to create about 1,500 jobs and produce plasma-derived critical care medicines plus bleeding-management and trauma-care products the company says will strengthen domestic supply for national security and emergency preparedness needs, with production targeted for the mid-2030s. The announcement followed weeks of dispute between York County and Rock Hill over how to split the tax-incentive package, including how much of the project’s special source revenue credit would flow to Rock Hill schools over the next 40 years, before Rock Hill’s city council voted 7 to 0 on July 24 to sell the land and approve the incentive deal. Octapharma is a plasma-derived therapies manufacturer this issue has tracked before through Grifols, the world’s largest plasma collector; this is the first US production footprint for Octapharma itself. Confidence: High on the investment figures and company plans, since they come directly from Octapharma’s own release and the South Carolina governor’s office; Medium on the incentive-fight details, since this run relied on regional television and newspaper coverage of county and city council votes rather than the meeting minutes themselves. Sources: Octapharma to build $1.5 billion state-of-the-art critical care manufacturing facility in Rock Hill, SC, PR Newswire, Octapharma selects York County for its first US manufacturing site, Office of South Carolina Governor Henry McMaster, $1.5B Octapharma investment approved for Rock Hill and York County, WSOC-TV.

13 billion dollars: that is Bristol Myers Squibb’s quarterly revenue, beating Wall Street’s estimate by more than 1 billion dollars, and the company raised its full year outlook for the second straight quarter. Bristol Myers Squibb reported second quarter 2026 revenue of 13.0 billion dollars, up 6 percent, well ahead of the roughly 11.7 to 11.9 billion dollar consensus estimate; non-GAAP earnings per share of 2.04 dollars beat the 1.60 to 1.61 dollar estimate, and GAAP earnings per share of 1.62 dollars was more than double the 0.64 dollars reported a year earlier. The company’s Growth Portfolio, the newer drugs including Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag that are meant to replace revenue lost to patent expirations, grew 15 percent to 7.6 billion dollars and now makes up nearly 60 percent of total revenue; Bristol Myers Squibb raised its full year 2026 revenue guidance to 49.0 to 50.0 billion dollars from a prior 46.0 to 47.5 billion dollars, and its non-GAAP earnings per share guidance to 6.75 to 7.00 dollars. Confidence: High, since the reported and guidance figures come directly from the company’s own SEC filing. Source: Bristol Myers Squibb Company Form 8-K, U.S. Securities and Exchange Commission.

750 million dollars: that is what a drugmaker and its contract manufacturer are spending to make more injectable medicine on US soil, including the GLP-1 drugs at the center of this year’s federal drug-pricing fight. Eli Lilly and Resilience announced July 30, 2026 a joint 750 million dollar investment to expand capacity for Lilly’s KwikPen injectable devices, used for its diabetes and obesity medicines, at Resilience’s Cincinnati-region manufacturing facilities; the expansion is expected to create at least 400 new jobs, bringing Resilience’s headcount in the region to more than 1,400, with full operations targeted for early 2027. The companies said they have produced more than 150 million doses together since their partnership began in 2023, and Resilience is separately relocating its corporate headquarters from San Diego to Blue Ash, Ohio, to sit closer to its production footprint. Confidence: High, since the investment figures and timeline come directly from the companies’ own joint announcement. Source: Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply, Business Wire.

2.2 billion dollars, an 86 percent premium: that is what a Belgian immunology drugmaker is paying for a biotech whose only real asset is a single antibody that just posted its first positive trial data. argenx agreed July 27, 2026 to acquire Forte Biosciences for 77 dollars a share in cash, a total equity value of approximately 2.2 billion dollars and a premium of roughly 86 percent to Forte’s volume-weighted average share price since it reported positive Phase 1b data in vitiligo on July 9, 2026; the deal is expected to close in the third quarter of 2026. The acquisition centers on FB102, a first-in-class antibody targeting the CD122 receptor with clinical proof of concept in vitiligo and celiac disease and potential across multiple autoimmune diseases; argenx had already made a strategic investment in Forte before the July 9 data turned that stake into a full buyout. Confidence: High, since the deal terms come directly from argenx’s own announcement. Source: argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline, GlobeNewswire.

FRONTIER SCAN. 442,000 patients: that is how many people a single back-office software vendor’s ransomware breach has now exposed, a business-cost story with no dedicated trade beat tracking it as its own vertical yet. Unlimited Technology Systems, a practice management and revenue cycle software vendor serving specialty healthcare practices nationwide, disclosed that an unauthorized actor accessed files between October 5 and October 10, 2025, an intrusion the company’s own security team first detected October 19, 2025; a notice filed with the Iowa attorney general’s office, one of at least five state filings, shows the company only began notifying affected individuals starting July 21, 2026, nine months after the breach and after a forensic investigation confirmed it was ransomware. State filings reviewed by trade press put the toll at more than 442,000 people nationwide, including roughly 148,000 South Carolina residents and 162,000 Iowa residents, with exposed data including health insurance and patient balance information, medical record numbers, diagnosis details, Social Security numbers and scanned identification documents, though not full medical records or financial account numbers; no extortion group has publicly claimed responsibility. The breach lands inside a documented 2026 surge, 410 ransomware attacks against healthcare organizations worldwide in the first half of 2026, up nearly 14 percent from the second half of 2025, with attacks on healthcare businesses such as billing and software vendors up nearly 35 percent, according to Comparitech’s tracking; a single vendor incident like this one ripples across the patients of every unrelated provider organization that outsources billing or scheduling to it. This is a corner of the business-cost ledger, cyber risk as a line item on provider and vendor balance sheets, this issue has not covered as its own thread before; HealthcareInfoSecurity’s near-daily breach coverage and Comparitech’s periodic ransomware roundups become this issue’s entry point for tracking it going forward. Confidence: High on the breach timeline and Iowa filing details, since they come directly from the company’s notice to the Iowa attorney general; Medium on the precise nationwide total, since it is compiled by trade press summing separate state-by-state disclosures rather than a single company-published figure. Sources: Notice of Data Breach, Unlimited Technology Systems filing with the Iowa Attorney General, Ransomware attack at health IT vendor exposes 442,000 patients’ data, Becker’s Hospital Review.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
Forte Biosciences	argenx	Biotech, immunology (anti-CD122 antibody FB102)	$2.2 billion cash ($77/share); expected close Q3 2026	argenx to Acquire Forte Biosciences, GlobeNewswire
Octapharma’s first US site (Rock Hill, SC)	Octapharma	Plasma-derived therapeutics manufacturing	$1.5 billion; approximately 1,500 jobs	Octapharma to build $1.5 billion facility, PR Newswire
Resilience’s Cincinnati-region facilities	Eli Lilly and Resilience (joint investment)	Contract manufacturing, GLP-1 and insulin injectable devices	$750 million; at least 400 new jobs	Resilience and Lilly Invest $750 Million, Business Wire
Freenome (public listing via SPAC merger with Perceptive Capital Solutions Corp)	Perceptive Capital Solutions Corp; PIPE led by Perceptive Advisors and RA Capital with Bain Capital Life Sciences	Digital health diagnostics, blood-based multi-cancer detection	Approximately $330 million gross proceeds; merger completed July 20, trading as Nasdaq: FRNM	Freenome to begin trading on Nasdaq following SPAC merger, Investing.com

agilon health and Clover Health both report second quarter results Wednesday, August 5; Privia Health and Oscar Health follow Thursday, August 6.